Please login to the form below

Not currently logged in
Email:
Password:

New deputy commissioner at US FDA

Robert Califf is a vice chancellor at Duke University

Robert Califf, FDAThe US FDA has named a Duke University vice chancellor as deputy commissioner for medical products and tobacco.

In his new role Dr Robert Califf will help lead the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Tobacco Products at the regulator.

He will also oversee the Office of Special Medical Programs in the Office of the Commissioner when he joins in late February.

FDA commissioner Margaret Hamburg, said: “Dr Califf's deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalise on, and improve upon, the significant advances we've made in medical product development and regulation over the last few years.”

Dr Califf is the current vice chancellor of clinical and translational research at Duke University in North Carolina in the US. His previous roles at Duke include director of the Duke Translational Medicine Institute (DTMI) and professor of medicine in the Division of Cardiology. He was also founding director of the Duke Clinical Research Institute.

He has previous experience with the FDA serving as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology.

29th January 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...